Posts Tagged ‘Hypoglycemia’

Potentially Fatal Errors with Certain Glucose Test Strips

Thursday, October 8th, 2009

Video originally created by FDA -- posted by Lawsuit.com on October 6, 2009

FDA is warning again that potentially fatal glucose monitoring errors can occur in patients who receive therapeutic products containing certain sugars other than glucose. These products include oral xylose, intravenous infusions that contain maltose or galactose, and peritoneal dialysis solutions that contain icodextrin, such as Extraneal. A more specific product list can be found below.

The problem is that some glucose meters use a type of test strip (GDH-PQQ) that cannot distinguish between glucose and these other sugars, so the reading on one of these test strips will reflect both the patient’s actual blood glucose and the other sugar the patient received. These falsely elevated readings can mask significant hypoglycemia, or they can lead to excessive insulin administration. This can result in severe hypoglycemia, coma and death. Other glucose test strip methodologies are not affected by the presence of non-glucose sugars.

FDA has received 13 reports of deaths associated with GDH-PQQ test strips that had documented interference from maltose or other non-glucose sugars. The deaths occurred in healthcare facilities. Ten of the 13 patients were receiving Extraneal peritoneal dialysis solution for renal failure. Three of the 13 patients were receiving maltose-containing substances. Patients were treated with insulin doses or insulin drips that were guided by falsely elevated blood sugar results. Six of the 13 deaths have occurred since 2008, despite previous warnings from FDA and others.

FDA is now recommending that healthcare facilities avoid using GDH-PQQ glucose test strips, which include several types of ACCU-CHEK, TRUEtest and Freestyle test strips.

If a facility does use GDH-PQQ test strips, FDA recommends additional precautions:

• Determine whether patients are receiving products that contain other sugars when they are admitted and periodically during their stay at the facility.

• If patients are receiving one of these interfering products, never use GDH-PQQ test strips to monitor their blood glucose. Instead, use only laboratory-based glucose assays. This also holds true for patients who are unresponsive or cannot communicate adequately.

• Educate the staff about this potentially fatal problem, and consider safeguards such as drug interaction alerts in computer order entry systems, patient profiles and charts. And for patients who are not receiving interfering products, periodically verify glucose meter readings with laboratory-based results.

FDA is working with glucose monitoring manufacturers to address problems with GDH-PQQ glucose test strips, and will continue to monitor adverse events associated with these products.

VN:F [1.5.6_840]
Rating: 0.0/10 (0 votes cast)
VN:F [1.5.6_840]
Rating: 0 (from 0 votes)

Potentially Fatal Glucose Monitoring Errors with Icodextrin

Tuesday, March 17th, 2009

Video originally created by FDA -- posted by Lawsuit.com on October 14, 2008

October 2008- The Institute for Safe Medication Practices (ISMP) is warning again about the possibility of potentially fatal glucose monitoring errors in patients receiving products that contain other sugars. These include oral xylose, parenterals that contain maltose or galactose, and peritoneal dialysis solutions that contain icodextrin. This issue was also reported in an earlier edition of FDA Patient Safety News.

The problem is that some point-of-care glucose meters use a type of test strip that cannot distinguish between glucose and other sugars. So in these cases, the meter’s reading of the test strip will reflect both the patient’s actual blood glucose and the other sugar the patient has received. This falsely elevated reading can lead to aggressive insulin treatment, which can result in hypoglycemic shock and death.

The latest ISMP report concentrates on Extraneal, a peritoneal dialysis solution containing icodextrin, which is metabolized in the body to maltose. The ISMP report notes that FDA has received 18 reports of hypoglycemic adverse events associated with Extraneal since it was first marketed in 2002. In three cases, the patient or a family member told the hospital staff about the potential problem, but the staff still relied on erroneous readings from portable monitors.

In one of the reported cases, a 62 year-old hospitalized dialysis patient on Extraneal therapy died from severe hypoglycemia because his treatment was based on falsely elevated glucose readings from an inappropriate meter. This occurred despite glucose readings from the hospital lab that were strikingly lower than those produced by the meter.

Test strips that cannot distinguish between glucose and other sugars contain reagents called GDH-PQQ or GDO. Other types of meters use reagents that are capable of distinguishing glucose from the other sugars. These reagents are called GDH-NAD, GDH-FAD, glucose oxidase and glucose hexokinase. It is important to check the package insert that comes with the test strips to determine which type of reagent they contain.

Here is what ISMP recommends to prevent these glucose monitoring errors in hospitals. Consider using only glucose meters that use test strips that can distinguish between glucose and other sugars. If you use meters and strips that cannot distinguish between the sugars, take these additional precautions:

•On admission and periodically during the hospital stay, find out whether the patient is receiving medications containing other sugars. If so, monitor glucose using only hospital laboratory methods.

•Periodically verify point-of-care blood glucose readings with laboratory results. This can detect errors in glucose meter readings early enough to prevent harm. This is especially important in patients who are unconscious or unable to communicate, since it may be difficult to ascertain the symptoms of hypoglycemia or the medication history.

•Educate the staff about this potentially fatal problem, and consider safeguards such as drug interaction alerts in computer order entry systems, patient profiles and charts.

VN:F [1.5.6_840]
Rating: 0.0/10 (0 votes cast)
VN:F [1.5.6_840]
Rating: 0 (from 0 votes)

Recall of ReliOn Insulin Syringes (Jan. 2009)

Thursday, January 15th, 2009

Video originally created by FDA -- posted by Lawsuit.com on January 14, 2009

Covidien, formerly Tyco Health Care, has recalled one lot of ReliOn disposable insulin syringes because of mislabeling. Some of the U-40 syringes in this lot were mistakenly labeled as U-100 syringes. Patients using U-100 insulin could experience a serious overdose if they used one of these mislabeled U-40 syringes, and that could lead to severe hypoglycemia and possibly death.The recalled lot is number 813900. These 1 cc, 31 gauge insulin syringes, which were mistakenly labeled U-100, were sold only by Wal-Mart and Sam’s Club, under the ReliOn name, from August 1 to October 8, 2008.FDA is urging healthcare professionals and patients to check their supplies of U-100 insulin syringes for the recalled products and not use them. The recalled syringes can be returned to Wal-Mart or Sam’s Club for replacement.

VN:F [1.5.6_840]
Rating: 0.0/10 (0 votes cast)
VN:F [1.5.6_840]
Rating: 0 (from 0 votes)

Mixups between Insulin U-100 and U-500 (April 2008)

Friday, December 12th, 2008

Video originally created by FDA -- posted by Lawsuit.com on September 02, 2008

September 2008- This story originally aired in April 2008. In this special edition of FDA PSN, we are repeating some of the most important safety issues that continue to pose a public health concern.The Institute for Safe Medication Practices (ISMP) recently described an increase in reports about mixups between insulin U-100 and insulin U-500. These errors could result in dangerous hyperglycemia or hypoglycemia. Mistakes have occurred when prescribers accidentally selected U-500 regular insulin from computer screens instead of U-100.ISMP has identified several possible reasons for these kinds of errors. For example, sometimes the two dosage forms appear one line apart on the screen, which makes it easy to select the wrong one. Also, depending on the screen size, the prescriber may see only the first few words of the product listing, so the drug concentration may not be visible. And finally, since the use of U-500 insulin is not common at present, prescribers may just assume that the only regular insulin that’s available is U-100 and not even look for the concentration on the screen. ISMP suggests that the use of U-500 insulin may be increasing due to the higher prevalence of obesity, the use of insulin pumps, and tight glucose control protocols in hospitalized patients.ISMP says that the major suppliers of drug information systems have agreed to add the word “concentrated” on their selection screens, immediately following the drug name and preceding “U-500″, which should help solve the problem. Until these updates appear in your system, here’s what ISMP recommends.• If U-500 is not commonly used in your facility, consider listing it differently from other insulins, so it does not appear on the same screen as other insulin products.• Consider adding a hard stop to all orders for U-500. This requires prescribers and pharmacists verify that the patient should be getting the U-500.• Pharmacies should consider not stocking U-500 if they do not have patients who use it.

VN:F [1.5.6_840]
Rating: 0.0/10 (0 votes cast)
VN:F [1.5.6_840]
Rating: 0 (from 0 votes)